Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VANIR: MVA-BN-RSV Vaccine in Adults ≥60 Years
NCT05238025Phase 3Terminated
- Sponsor
- Bavarian Nordic
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of MVA-BN-RSV in respiratory syncytial virus infection (RSV), sponsored by Bavarian Nordic. Started Apr 2022; status: terminated.
02
Drugs
MVA-BN-RSV
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05238025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238025.